查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992673

球孢子菌病市場：2026-2032年全球市場預測（依藥物類別、感染類型、病原菌種類、給藥途徑、通路、最終用戶及病患類型分類）

Coccidioidomycosis Market by Drug Class, Infection Type, Species, Route Of Administration, Distribution Channel, End User, Patient Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年球孢子菌病市場價值為 5.0313 億美元，預計到 2026 年將成長至 5.3764 億美元，複合年成長率為 7.19%，到 2032 年將達到 8.1845 億美元。

主要市場統計數據
基準年 2025 5.0313億美元
預計年份：2026年 5.3764億美元
預測年份：2032年 8.1845億美元
複合年成長率 (%) 7.19%

對球孢子菌病的臨床挑戰進行全面概述，並探討重組診斷和治療服務及策略重點的系統性因素。

球孢子菌病，在流行地區常被稱為“谷熱”，在臨床管理、公共衛生監測和藥物供應等方面都面臨著許多挑戰。本導論分析整合了現代臨床實踐、診斷技術的進步以及治療方法，旨在闡明臨床、監管和商業領域的相關人員為何必須重新評估其工作重點。球孢子菌病的症狀從可自癒的呼吸道疾病到慢性全身性疾病不等，因此早期診斷和適當的抗真菌治療至關重要，同時也凸顯了對更有效的診斷和治療途徑日益成長的需求。

不斷發展的臨床診斷和治療方法，與供應鏈韌性和不斷變化的流行病學情況相互交織，正在重塑護理路徑和相關人員的策略。

球孢子菌病的格局正在經歷一場變革，這主要得益於診斷技術的進步、治療策略的改進以及公共衛生系統對該病認知的提高。照護現場和檢查室分子檢測縮短了診斷時間，使臨床醫生能夠更早啟動標靶抗真菌治療，進而改變了住院和門診追蹤模式。同時，受人口流動和氣候變遷的影響，傳統流行區以外地區對該病的認知也在不斷提高，這促使相關人員重新評估監測系統和臨床醫生教育計畫。

貿易政策和關稅措施的變化迫使供應鏈重組，籌資策略進行改革，以維持抗真菌治療和臨床用品的供應。

關稅政策趨勢的累積影響波及整個醫藥供應鏈及成本結構，對抗菌藥物及相關臨床材料造成顯著影響。進口活性藥物成分和成品的關稅不斷提高，凸顯了供應鏈多元化的必要性，迫使生產商和採購團隊評估替代籌資策略，並考慮區域性製造地，以降低關稅波動帶來的風險。這種重組不僅影響定價，還影響庫存策略以及經銷商和醫療服務提供者之間的合約關係。

從臨床和商業性觀點進行細分，揭示了基於藥物類別、感染疾病表現型、給藥途徑、分銷管道、最終用戶和患者類型的不同需求。

細緻的市場區隔觀點揭示了治療方法選擇和護理路徑如何與獨特的臨床和商業性需求交織在一起。依藥物類別分析，市場可分為Azole和Polyenes，Azole可進一步細分為Fluconazole、Itraconazole、Ketoconazole和Voriconazole。每種藥物都具有其獨特的療效、耐受性和藥物交互作用特徵，有助於在急性、慢性及播散性疾病狀態下選擇合適的治療方法。區分感染類型（慢性與播散）有助於明確哪些地區門診口服治療較為普遍，哪些地區在醫院環境中初始治療必須採用靜脈注射。考慮到球孢子菌屬中類球孢子菌（Coccidioides imitis）和波薩達斯球孢子菌（Coccidioides posadasii）之間的種屬差異，可以發現一些細微的診斷和流行病學差異，這些差異可能會影響區域監測和臨床實驗室的設計。

美洲、歐洲、中東、非洲和亞太地區在疫情情勢、臨床能力和法規結構方面的區域差異，造成了不同的進入管道和策略重點。

區域動態對不同地區的疾病發生率、臨床實務和市場趨勢有顯著影響。在美洲，疫情熱點地區集中了臨床專家、診斷基礎設施和專科醫療管道，有助於快速識別病例並啟動治療。同時，這些地區內外的人口流動提高了臨床意識，並推動了對可擴展診斷方法的需求。歐洲、中東和非洲的情況則更為複雜，零星輸入病例與特定醫療中心不斷提升的診斷能力並存，因此需要針對臨床醫生開展有針對性的培訓，並跨境監測合作，以確保及時發現和控制疫情。

我們的競爭策略專注於產生證據、最佳化配方、建立經銷夥伴關係以及整合診斷技術，從而為臨床醫生和醫療保健提供者創造差異化的價值提案。

在整體競爭格局中，各公司和機構正採取差異化策略，以滿足臨床需求並鞏固其在抗真菌藥物和診斷領域的地位。一些機構致力於透過研究者主導的試驗和真實世界數據收集來加強臨床證據，以證明其在慢性病和播散性疾病中的療效和長期安全性。另一些機構則優先考慮製劑創新，致力於最佳化口服生物有效性，並開發便於患者使用的給藥方案，以提高門診患者的用藥依從性。隨著相關人員努力在監管和關稅壓力下確保高效的分銷和供應鏈的持續性，製造商、合約研究組織 (CRO) 和專科藥房之間的策略合作日益普遍。

為領導者提供實際的策略行動，以協調開發、分銷和臨床教育工作，同時加強供應鏈和市場進入管道。

行業領導者應採取一系列切實可行的措施，以最大限度地發揮臨床進展的益處並降低營運風險。首先，他們應透過投資進行對照研究，使臨床開發重點與未滿足的醫療需求保持一致，從而揭示Fluconazole、Itraconazole、Ketoconazole和Voriconazole在各患者亞群中的相對優勢，同時支持用於改進兒童製劑的研究。其次，他們應透過實現原料藥成分來源多元化和探索區域生產夥伴關係來增強供應鏈韌性，從而降低貿易中斷和關稅相關成本衝擊帶來的影響。

嚴謹的多面向研究框架，結合文獻分析、專家訪談和三角資料檢驗，檢驗了臨床、營運和政策方面的見解。

本分析的基礎研究結合了多方面資訊和系統檢驗，以確保得出可靠且實用的見解。二級研究涵蓋了同行評審文獻、臨床指南、監管出版刊物和公共衛生監測報告，旨在建立關於疾病流行病學、診斷性能和治療方法的全面證據基礎。在此文獻基礎上，我們開展了有針對性的初級研究，包括對臨床專業人員、醫院藥劑師、供應鏈經理和經銷商進行結構化訪談，以獲取真實世界的運營見解並檢驗新興主題。

必須強調，需要根據證據進行策略調整，以應對臨床、營運和政策方面的挑戰，並改善醫療服務取得、治療效果和供應韌性。

總之，球孢子菌病相關的臨床、商業和政策環境仍在不斷演變，需要協調一致的應對措施，將診斷、治療、供應鏈管理和臨床醫生參與等環節有機結合。分子和血清學檢測技術的進步，以及Azole和Polyenes藥物在慢性及播散性病例中更為精細的治療應用，為透過教育和合理用藥管理改善患者預後提供了契機。同時，貿易政策和關稅趨勢凸顯了積極主動的供應鏈規劃以及生產和採購資源的策略性配置對於維持醫療服務的連續性至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：球孢子菌病市場：依藥物類別分類

  • Azole
    • Fluconazole
    • Itraconazole
    • Ketoconazole
    • Voriconazole
  • Polyenes

第9章：球孢子菌病市場：依感染類型分類

  • 慢性的
  • 傳播

第10章：球孢子菌病市場：依病原體分類

  • 粗球孢子菌
  • 波薩達斯球孢子菌

第11章：球孢子菌病市場：依給藥途徑分類

  • 靜脈
  • 口服

第12章：球孢子菌病市場：依通路分類

  • 實體零售
  • 線上零售

第13章：球孢子菌病市場：依最終用戶分類

  • 診所
  • 醫院
  • 研究機構
  • 專業醫療中心

第14章：球孢子菌病市場：依患者類型分類

  • 成人
  • 兒童

第15章：球孢子菌病市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：球孢子菌病市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：球孢子菌病市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國球孢子菌病市場

第19章：中國球孢子菌病市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • CELLTRION INC.
  • Gilead Sciences, Inc.
  • IMMY
  • Laboratory Corporation of America Holdings
  • Mayne Pharma Group Limited
  • Merck & Co., Inc.
  • Meridian Bioscience, Inc.
  • Meridian Bioscience, Inc.
  • Mycovia Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Quest Diagnostics Incorporated
  • Scynexis, Inc.
  • Shionogi & Co., Ltd.
Product Code: MRR-81515600A08C

The Coccidioidomycosis Market was valued at USD 503.13 million in 2025 and is projected to grow to USD 537.64 million in 2026, with a CAGR of 7.19%, reaching USD 818.45 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 503.13 million
Estimated Year [2026] USD 537.64 million
Forecast Year [2032] USD 818.45 million
CAGR (%) 7.19%

Comprehensive contextual overview of coccidioidomycosis clinical challenges and systemic factors reshaping diagnosis treatment delivery and strategic priorities

Coccidioidomycosis, often referred to as valley fever in endemic regions, presents a multifaceted challenge spanning clinical management, public health surveillance, and pharmaceutical supply. This introductory analysis synthesizes contemporary clinical practice, diagnostic evolution, and therapeutic approaches to frame why stakeholders across clinical, regulatory, and commercial spheres must recalibrate priorities. The disease's variable presentation, ranging from self-limited respiratory illness to chronic and disseminated systemic disease, places a premium on timely diagnosis and appropriate antifungal therapy, while also driving demand for more effective diagnostics and treatment pathways.

Recent advances in antifungal development, improvements in molecular and serologic diagnostics, and heightened focus on vulnerable populations such as immunocompromised patients and certain demographic cohorts have collectively reshaped care paradigms. Simultaneously, shifting healthcare delivery models and evolving payer dynamics influence how treatments are accessed across inpatient and outpatient settings. This introduction sets the stage for a deeper assessment of systemic shifts, policy impacts, segmentation-specific implications, regional nuances, and practical recommendations that follow. The goal is to equip leaders with a concise yet robust foundation to interpret downstream analyses and to act decisively in an environment of accelerating clinical and commercial change.

Evolving clinical diagnostics and therapeutic modalities intersect with supply chain resilience and shifting epidemiology to reshape care pathways and stakeholder strategies

The landscape for coccidioidomycosis is undergoing transformative shifts driven by advances in diagnostics, therapeutic strategy refinement, and expanded awareness across public health systems. Point-of-care and laboratory-based molecular assays are shortening time to diagnosis, enabling clinicians to initiate targeted antifungal therapy earlier, which in turn changes patterns of hospital utilization and outpatient follow-up. Concurrently, growing recognition of the disease outside historically endemic zones, influenced by population mobility and climate-related shifts, has compelled stakeholders to reassess surveillance frameworks and clinician education programs.

Therapeutic portfolios are also evolving. There is a clear trend toward optimizing azole therapy selection based on better understanding of pharmacokinetics, drug-drug interactions, and patient tolerance, while intravenous formulations remain essential for severe and disseminated cases that require hospital-based care. These clinical refinements are prompting revisions in treatment algorithms and influencing the distribution of demand across hospitals, clinics, and specialty centers. In parallel, supply chain resilience is becoming a strategic priority as manufacturers and distributors adapt to changes in raw material sourcing, regulatory complexity, and channel dynamics. Taken together, these shifts necessitate integrated planning across clinical development, commercial operations, and public health policy to translate innovation into improved patient outcomes and sustained access.

Shifts in trade policy and tariff measures are compelling supply chain realignment and procurement strategy reform to preserve access to antifungal treatments and clinical supplies

The cumulative impact of tariff policy developments has rippled through pharmaceutical supply chains and cost structures with material implications for antifungal therapies and related clinical supplies. Increased duties on imported active pharmaceutical ingredients and finished formulations have heightened the need for supply chain diversification, prompting manufacturers and procurement teams to evaluate alternative sourcing strategies and to consider regional manufacturing hubs that reduce exposure to tariff volatility. This realignment affects not only pricing considerations but also inventory strategies and contractual arrangements with distributors and healthcare providers.

Tariff-driven cost pressures can accelerate the consolidation of purchasing among larger hospital systems and specialty centers that possess greater negotiating power and supply chain sophistication. At the same time, smaller clinics and independent providers may face tighter margins and increased reliance on wholesalers and third-party logistics providers to manage procurement complexity. Manufacturers responding to these dynamics may prioritize product formulations and routes of administration that balance clinical utility with supply chain feasibility, such as favoring oral agents for chronic management where stability and distribution are more straightforward. Overall, the tariff environment underscores the importance of proactive supply chain mapping, scenario planning, and strategic partnerships to safeguard access to essential antifungal therapies while maintaining affordability across care settings.

Segmented clinical and commercial perspectives reveal differentiated needs across drug classes infection phenotypes routes of administration distribution channels end users and patient types

A nuanced segmentation lens reveals how therapeutic choices and care pathways intersect with distinct clinical and commercial imperatives. When analyzed by drug class, the market divides between azoles and polyenes, with azoles further differentiated into fluconazole, itraconazole, ketoconazole, and voriconazole, each offering a distinct efficacy tolerability and drug interaction profile that informs regimen selection for acute chronic and disseminated presentations. Differentiation by infection type-chronic versus disseminated-clarifies where outpatient oral therapies predominate versus where intravenous interventions are essential for initial management in hospital settings. Species-level considerations between Coccidioides immitis and Coccidioides posadasii contribute to subtle diagnostic and epidemiologic distinctions that can influence regional surveillance and clinical trial design.

Route of administration remains a pivotal segmentation axis, with intravenous delivery reserved for severe disease requiring rapid therapeutic levels and oral formulations facilitating long-term management and improved patient adherence in ambulatory care. Distribution channel segmentation into offline retail and online retail highlights evolving patient access patterns, with digital pharmacies and e-prescribing altering fulfillment timelines and adherence support. End user segmentation across clinics hospitals research institutes and specialty centers underscores diverse procurement behaviors and clinical workflows, affecting how products are positioned and supported commercially. Finally, patient type segmentation into adults and pediatrics emphasizes distinct dosing formulations safety profiles and the need for tailored clinical evidence to support pediatric use. Together these segmentation dimensions create a matrix that informs product development priorities, commercial access strategies, and clinical education efforts across the care continuum.

Regional variations in endemicity clinical capabilities and regulatory frameworks drive distinct access pathways and strategic priorities across the Americas EMEA and Asia Pacific

Regional dynamics exert a profound influence on disease incidence clinical practice and market behavior across distinct geographies. In the Americas, endemic hotspots concentrate clinical expertise, diagnostic infrastructure, and specialty care pathways that shape rapid case identification and treatment initiation, while population mobility within and beyond these regions spreads clinical awareness and drives demand for scalable diagnostics. Europe Middle East & Africa present heterogenous landscapes where sporadic imported cases coexist with growing diagnostic capacity in select centers, prompting targeted clinician education and cross-border surveillance collaborations to ensure timely recognition and management.

Asia-Pacific shows a mix of emerging awareness and variable access to antifungal therapies, with disparities in hospital infrastructure and distribution networks influencing how care is delivered in urban centers versus peripheral regions. Regional regulatory frameworks and reimbursement environments further modulate adoption of newer diagnostics and therapeutics, necessitating tailored market entry strategies that account for local policy, clinical practice norms, and distribution partnerships. Across all regions, coordinated capacity-building for laboratories and continuing medical education for frontline clinicians remains critical to improving outcomes and reducing delays in diagnosis and treatment initiation.

Competitive strategies emphasize evidence generation formulation optimization distribution partnerships and diagnostics integration to create differentiated value propositions for clinicians and providers

Across the competitive landscape, companies and institutions are adopting differentiated strategies to address clinical needs and to strengthen their position in antifungal therapeutics and diagnostics. Some organizations concentrate on enhancing clinical evidence through investigator-initiated studies and real-world data collection to demonstrate comparative effectiveness and long-term safety in chronic and disseminated disease. Others prioritize formulation innovation, optimizing oral bioavailability or creating patient-friendly dosing regimens that support adherence in outpatient settings. Strategic partnerships between manufacturers, contract development organizations, and specialty pharmacies are increasingly common as stakeholders seek to streamline distribution and to ensure continuity of supply in the face of regulatory and tariff pressures.

In parallel, diagnostic firms are investing in higher-sensitivity assays and multiplex platforms that enable faster differentiation of etiologic agents, thereby supporting targeted therapy selection. Institutional end users such as hospitals, clinics, and research institutes are escalating investments in clinician training and in antimicrobial stewardship programs that align antifungal selection with best practice guidelines. Collectively, these company-level moves reflect a shift toward integrated offerings that combine therapeutic agents with diagnostic and educational support to create differentiated value propositions for physicians payers and procurement teams.

Practical strategic actions for leaders to align development distribution and clinical education efforts while strengthening supply chains and market access pathways

Industry leaders should adopt a pragmatic set of actions to capitalize on clinical advances and to mitigate operational risks. First, align clinical development priorities with unmet needs by investing in comparative studies that clarify the relative advantages of fluconazole itraconazole ketoconazole and voriconazole across patient subgroups, while also supporting research into improved formulations for pediatric use. Second, strengthen supply chain resilience by diversifying sourcing for active pharmaceutical ingredients and by exploring regional manufacturing partnerships that reduce exposure to trade disruptions and tariff-related cost shocks.

Third, develop comprehensive market access strategies that incorporate both offline retail and online retail channels, recognizing how e-prescribing and digital pharmacy services reshape patient fulfillment and adherence. Fourth, engage proactively with end users-clinics hospitals research institutes and specialty centers-to deliver tailored clinical education and stewardship resources that facilitate appropriate antifungal use across chronic and disseminated cases. Finally, pursue collaborative opportunities with diagnostic developers to co-develop bundled solutions that streamline diagnosis-to-treatment pathways and support payer discussions by demonstrating clinical and operational value. These recommendations prioritize agility and integration to ensure sustained access and improved patient outcomes while navigating policy and market complexity.

Rigorous multi-source research framework integrating literature synthesis expert interviews and data triangulation to validate clinical operational and policy insights

The research underpinning this analysis combined multi-source intelligence and methodical validation to ensure robust, actionable findings. Secondary research encompassed peer-reviewed literature clinical guidelines regulatory publications and public health surveillance reports to construct a comprehensive evidence base on disease epidemiology diagnostic performance and therapeutic approaches. This literature-driven foundation was augmented by targeted primary research consisting of structured interviews with clinical experts, hospital pharmacists, supply chain managers, and distributors to capture real-world operational insights and to validate emergent themes.

Data synthesis employed triangulation techniques to reconcile findings across clinical evidence, procurement practices, and regional policy contexts. The methodology prioritized transparency in source attribution and critical assessment of evidence quality, placing greater weight on high-quality randomized trials and validated diagnostic performance studies while contextualizing observational and real-world data. Where gaps existed, expert elicitation provided interpretive guidance to ensure conclusions remained clinically plausible and operationally relevant. The resulting analytical framework supports reproducible insight generation and can be adapted for ongoing surveillance and periodic report updates.

Synthesis of clinical operational and policy imperatives highlighting the need for coordinated evidence aligned strategies to improve access outcomes and supply resilience

In conclusion, the evolving clinical, commercial, and policy landscape around coccidioidomycosis requires coordinated responses that bridge diagnostics therapeutics supply chain management and clinician engagement. Advances in molecular and serologic testing, coupled with more refined therapeutic use of azoles and polyenes across chronic and disseminated presentations, create opportunities to improve patient outcomes when translated into practice through education and stewardship. At the same time, trade policy and tariff developments emphasize the importance of proactive supply chain planning and the strategic allocation of manufacturing and procurement resources to maintain continuity of care.

Strategic alignment among manufacturers distributors providers and payers will be essential to converting scientific and operational progress into tangible improvements in access and outcomes. Continued investment in evidence generation, coupled with regionally tailored access strategies and integrated diagnostic-treatment solutions, will enable stakeholders to navigate uncertainty and to deliver better care for affected patients. This synthesis offers a basis for informed decision-making and underscores the necessity of agile, evidence-aligned approaches in an environment of shifting epidemiology and policy dynamics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coccidioidomycosis Market, by Drug Class

  • 8.1. Azoles
    • 8.1.1. Fluconazole
    • 8.1.2. Itraconazole
    • 8.1.3. Ketoconazole
    • 8.1.4. Voriconazole
  • 8.2. Polyenes

9. Coccidioidomycosis Market, by Infection Type

  • 9.1. Chronic
  • 9.2. Disseminated

10. Coccidioidomycosis Market, by Species

  • 10.1. Coccidioides Immitis
  • 10.2. Coccidioides Posadasii

11. Coccidioidomycosis Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral

12. Coccidioidomycosis Market, by Distribution Channel

  • 12.1. Offline Retail
  • 12.2. Online Retail

13. Coccidioidomycosis Market, by End User

  • 13.1. Clinics
  • 13.2. Hospitals
  • 13.3. Research Institutes
  • 13.4. Specialty Centers

14. Coccidioidomycosis Market, by Patient Type

  • 14.1. Adults
  • 14.2. Pediatrics

15. Coccidioidomycosis Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Coccidioidomycosis Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Coccidioidomycosis Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Coccidioidomycosis Market

19. China Coccidioidomycosis Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. CELLTRION INC.
  • 20.6. Gilead Sciences, Inc.
  • 20.7. IMMY
  • 20.8. Laboratory Corporation of America Holdings
  • 20.9. Mayne Pharma Group Limited
  • 20.10. Merck & Co., Inc.
  • 20.11. Meridian Bioscience, Inc.
  • 20.12. Meridian Bioscience, Inc.
  • 20.13. Mycovia Pharmaceuticals, Inc.
  • 20.14. Pfizer Inc.
  • 20.15. Quest Diagnostics Incorporated
  • 20.16. Scynexis, Inc.
  • 20.17. Shionogi & Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COCCIDIOIDOMYCOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COCCIDIOIDOMYCOSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA COCCIDIOIDOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY KETOCONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY KETOCONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY KETOCONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES IMMITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES IMMITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES IMMITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES POSADASII, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES POSADASII, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES POSADASII, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 156. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 158. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 183. G7 COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 185. G7 COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. G7 COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. G7 COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. NATO COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 192. NATO COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 194. NATO COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. NATO COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. NATO COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. NATO COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA COCCIDIOIDOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)